Could We Maintain the Initial Efficacy of Triple Sequential Combination Therapies with Selexipag Against Progressive Deterioration Risk in Patients with Pulmonary Arterial Hypertension: Insights from a Single-Center Study?
Earlier escalation to triple therapy with selexipag may improve outcomes. Baseline risk-but not achieved selexipag dose-was associated with survival. A possible decline in treatment effect after 1 year warrants further investigation.
Authors
- Hacer Ceren Tokgöz (ORCID: https://orcid.org/0000-0001-8187-7290)
Institutions
- Kartal Koşuyolu High Specialization Training and Research Hospital (TR)
Publication Details
- Journal
- The Anatolian Journal of Cardiology
- Published
- 2026-01-01
- DOI
- https://doi.org/10.14744/anatoljcardiol.2025.5976
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00